½ÃÀ庸°í¼­
»óǰÄÚµå
1496006

¼¼°èÀÇ °ñ ½Ã¸àÆ® ½ÃÀå : ¿¹Ãø(2024-2029³â)

Global Bone Cement Market - Forecasts from 2024 to 2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Knowledge Sourcing Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 160 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

°ñ ½Ã¸àÆ®(Bone Cement) ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È CAGR 5.67%·Î ¼ºÀåÇÏ¿© 2022³â 17¾ï 8,000¸¸ ´Þ·¯¿¡¼­ 2029³â¿¡´Â 26¾ï 1,900¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

°ñ ½Ã¸àÆ®´Â Æú¸®¸ÞÆ¿¸ÞŸũ¸±·¹ÀÌÆ®(PMMA), ÀλêÄ®½·, À¯¸® Æú¸®¾ËÄɳ뿡ÀÌÆ®ÀÇ ºÐ¸»À» ¾×ü ´Ü·®Ã¼¿Í È¥ÇÕÇÏ¿© ¾òÀº ÇÕ¼º »ýü Àç·á¸¦ ¸»ÇÕ´Ï´Ù. ÀÌ ½Ã¸àÆ®¿¡´Â ÃÊ Á¢Âø ±â´ÉÀÌ ÀÖ¾î °í°üÀý, ¹«¸­ °üÀý, Àΰø °üÀý ġȯ¼ú µî Á¤Çü¿Ü°ú ¼ö¼ú¿¡ ÀÀ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. Àڱ⠼öº¹¼º°ú Àΰø °üÀý·Î ÀÛ¿ëÇÏ´Â ´É·ÂÀº ÀÇ·á ºÐ¾ß¿¡¼­ °ñ ½Ã¸àÆ® ¼ö¿ä¸¦ °ßÀÎÇÕ´Ï´Ù.

Ä¡¸íÀûÀÎ ºÎ»ó, »ç°í, Á¤Çü¿Ü°ú ¼ö¼ú »ý»êÀÚ Áõ°¡, ³ë·É Àα¸ Áõ°¡¿Í ÇÔ²² °ñ ½Ã¸àÆ® ½ÃÀå¿¡ Ãß°¡ ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹³ëµ¿Åë°è±¹ÀÌ Á¦°øÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é 2019³â ¹Ì±¹¿¡¼­ ¹ß»ýÇÑ »ç¸Á³ëµ¿ÀçÇØ °Ç¼ö´Â 5,333°ÇÀ̸ç 2015³â ¹ß»ýÇÑ 4,836°Ç¿¡ ºñÇØ 10.3%ÀÇ ´ëÆø Áõ°¡¸¦ º¸¿´½À´Ï´Ù.

ÀÌ¿Í °°Àº »ç¸ÁÀçÇØ Áõ°¡¿¡ µû¶ó »À¿Í °ü·ÃµÈ ¸ðµç ºÎ»ó Ä¡·á¿¡¼­ °ñ ½Ã¸àÆ®ÀÇ »ç¿ë ¹üÀ§µµ È®´ëµÇ¾î ¿¹Ãø ±â°£ µ¿¾È °ñ ½Ã¸àÆ® ½ÃÀå ¼ö¿ä¿Í ¼ºÀåÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¼¼ºÐÈ­´Â Æú¸®¸ÞÆ¿¸ÞŸũ¸±·¹ÀÌÆ®, ÀλêÄ®½·, À¯¸® Æú¸®¾ËÄɳ뿡ÀÌÆ®·Î ±¸ºÐµË´Ï´Ù. Æú¸®¸ÞÆ¿¸ÞŸũ¸±·¹ÀÌÆ® ºÎ¹®Àº °ñ ½Ã¸àÆ® ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ºñ±³Àû ³ôÀº ¼ºÀå·üÀÌ ¿¹»óµË´Ï´Ù.

Æú¸®¸ÞÆ¿ ¸ÞŸũ¸±·¹ÀÌÆ®´Â ±â°èÀû °­µµ°¡ dzºÎÇÏ°í µ¶¼ºÀÌ ÀûÀ¸¸ç ÀÚ°¡ °æÈ­ Ư¼ºÀÌ °³¼±µÇ¾î °üÀý º¸Ã¶¹° °íÁ¤ ½Ã Àû¿ë¼ºÀÌ ³ô½À´Ï´Ù. µû¶ó¼­ »À¿Í ÀÓÇöõÆ® »çÀÌÀÇ °ø°£ ÃæÀüÀç ¿ªÇÒÀ» ÇÏ´Â PMMA °ñ ½Ã¸àÆ®´Â ÀÓÇöõÆ®ÀÇ °íÁ¤·ÂÀ» Çâ»ó½Ãŵ´Ï´Ù. Æú¸®¸ÞÆ¿ ¾ÆÅ©¸±·¹ÀÌÆ® °ñ ½Ã¸àÆ®ÀÇ °í¼º´É Ư¼º°ú ºñ¿ë È¿À²¼º ¹× ³ôÀº ³»±¸¼ºÀº ÇâÈÄ °üÀý º¸Ã¶ ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃÄÑ ¿¹Ãø ±â°£ µ¿¾È ÇØ´ç ºÎ¹® ¼ºÀå°ú Àüü °ñ ½Ã¸àÆ® ½ÃÀå ¼ºÀåÀ» ÃËÁø ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ :

  • Á¤Çü¿Ü°ú ¼ö¼ú °Ç¼ö ±ÞÁõÀÌ °ñ ½Ã¸àÆ® ½ÃÀå ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

°ñ ½Ã¸àÆ®´Â ¼Õ»óµÈ »À ºÎºÐÀ» Àΰø »À·Î ´ëüÇÏ´Â Á¤Çü¿Ü°ú ¼ö¼ú¿¡¼­ ³ôÀº Àû¿ë¼ºÀ» °¡Áö¸ç Àΰø »À¸¦ Á¦ÀÚ¸®¿¡ °íÁ¤Çϱâ À§ÇØ °ñ ½Ã¸àÆ®°¡ »ç¿ëµË´Ï´Ù. Á¤Çü¿Ü°ú ¼ö¼úÀÇ ¼ö´Â ƯÈ÷ ³ëÀÎÀÇ °üÀý°ú »À ÅëÁõ Áõ°¡, °ñ°üÀý¿° ¹× ±³Åë »ç°í Áõ°¡¿¡ µû¶ó ¸Å³â Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹ Á¤Çü¿Ü°úÇÐȸ(American Academy of Orthopedic Surgeons)ÀÇ ¿¬·Ê º¸°í¼­¿¡ µû¸£¸é 2021³â ¹Ì±¹¿¡¼­ ½Ç½ÃµÈ Àΰø ½½°üÀý ġȯ¼ú°ú Àΰø °í°üÀý ġȯ¼úÀÇ °Ç¼ö´Â 240¸¸ °ÇÀ¸·Î 2020³â¿¡ ½ÃÇàµÈ ¼ö¼ú °Ç¼ö¿¡ ºñÇØ 18.3% Áõ°¡¸¦ º¸¿´½À´Ï´Ù.

¶ÇÇÑ È£ÁÖ Á¤Çü¿Ü°úÇÐȸ(Australia Orthopaedic Association National Joint Replacement Surgery Registry)ÀÇ 2022³â ¿¬Â÷ º¸°í¼­¿¡ µû¸£¸é 2021³â È£ÁÖ¿¡¼­ º¸°íµÈ Àΰø°üÀý ġȯ¼úÀÇ ÃѼö´Â 185¸¸ °ÇÀ¸·Î, ±× Áß ¹«¸­ °üÀý ġȯ ¼ö¼úÀº 68,466°Ç¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß°í, °í°üÀý ġȯ¼úÀº 52,787°ÇÀ̾ú½À´Ï´Ù. 2021³â Àΰø°üÀý ġȯ¼úÀÇ Àü¹ÝÀûÀÎ Áõ°¡À²Àº 2020³â Àΰø°üÀý ġȯ¼ú ¼ö¼ú °Ç¼ö¿¡ ºñÇØ 7.6%¿´½À´Ï´Ù.

ÀÌ·¯ÇÑ Á¤Çü¿Ü°ú ¼ö¼ú °Ç¼ö Áõ°¡¿¡ µû¶ó, »ÀÀÇ Æ´»õ ÃæÀüÀç·Î¼­ ±â´ÉÇÏ´Â °ñ ½Ã¸àÆ® ¼ö¿ä¿Í ¼Òºñµµ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í, ¿¹Ãø ±â°£ ÁßÀÇ °ñ ½Ã¸àÆ® ½ÃÀåÀÇ ¼ºÀå¿¡ ¹àÀº Àü¸ÁÀ» °¡Á®¿À°í ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÓÇöõÆ®ÀÇ ÇÕº´Áõ°ú ÇÔ²² °ñ ½Ã¸àÆ®¸¦ ÁغñÇÏ´Â µ¥ ¾öû³­ ºñ¿ëÀÌ ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ½Ã¸àÆ® ½ÃÀåÀÇ ¼ºÀåÀ» ¹æÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

  • °üÀý°ú »À ¼Õ»óÀÇ ¹ß»ý·ü Áõ°¡´Â °ñ ½Ã¸àÆ® ½ÃÀåÀ» ÃßÁøÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

°ñ ½Ã¸àÆ® ½ÃÀåÀº Á¤Çü¿Ü°úÀû °³ÀÔÀ» ÀÚÁÖ ÇÊ¿ä·Î ÇÏ´Â ½ºÆ÷Ã÷ ºÎ»ó Áõ°¡¿¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. °ñ ½Ã¸àÆ®´Â Æú¸®¸ÞÆ¿ ¸ÞŸũ¸±·¹ÀÌÆ®·Îµµ ¾Ë·ÁÁ® ÀÖÀ¸¸ç °üÀý ġȯ¼ú¿¡¼­ ÀÓÇöõÆ®¸¦ »À¿¡ °íÁ¤ÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ½ºÆ÷Ã÷ Âü¿©¿Í ½Åü Ȱµ¿ÀÇ ¼¼°è Áõ°¡·Î ½ºÆ÷Ã÷ °ü·Ã ºÎ»ó, ƯÈ÷ »À¿Í °üÀý¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ºÎ»óÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

°¨¿°Áõ ¿¹¹æÀ» À§ÇÑ Ç×»ýÁ¦ ÇÔÀ¯ ½Ã¸àÆ®¿Í »ýüÀûÇÕ¼º Çâ»ó µî °ñ ½Ã¸àÆ® ±â¼úÀÇ Áøº¸·Î ´Ù¾çÇÑ Á¤Çü¿Ü°ú ¿ëµµ·Î ¼±È£ÇÏ°í »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. °í·ÉÈ­°¡ ÁøÇàµÇ¾î Ȱµ¿ÀûÀÎ ¶óÀÌÇÁ½ºÅ¸ÀÏÀ» À¯ÁöÇÏ´Â °ÍÀÌ Áß½ÃµÇ°Ô µÈ °á°ú, ÅðÇ༺ °üÀý ÁúȯÀ̳ª ½ºÆ÷Ã÷ °ü·Ã ºÎ»óÀÇ À¯º´·üÀÌ ³ô¾ÆÁö°í, Á¤Çü¿Ü°ú ¼ö¼ú ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

°ñ ½Ã¸àÆ®¸¦ »ç¿ëÇÏ´Â Á¤Çü¿Ü°ú ¼ö¼úÀº ÀçȰÀ» Áö¿øÇÏ°í °³ÀÎÀÇ À̵¿¼º°ú ±â´ÉÀÇ È¸º¹À» °¡´ÉÇϰÔÇÕ´Ï´Ù. ½ºÆ÷Ã÷ ºÎ»óÀÇ ¿µÇâÀ¸·Î °ñ ½Ã¸àÆ® ½ÃÀå È®´ë´Â ¾ÕÀ¸·Îµµ °è¼ÓµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ :

  • °í°¡ÀÇ ºñ¿ë°ú ¾ö°ÝÇÑ ÀÓ»ó µ¥ÀÌÅÍ ¿ä±¸ »çÇ×Àº ½ÃÀå ¼ºÀåÀ» ¾ïÁ¦ÇÒ ¼ö ÀÖ½À´Ï´Ù.

°ñ ½Ã¸àÆ®ÀÇ °³¹ßÀº ¾öû³­ ¿¬±¸ °³¹ß ÅõÀÚ°¡ ÇÊ¿äÇÑ ºñ¿ë°ú ½Ã°£ÀÌ ¸¹ÀÌ °É¸®´Â °úÁ¤ÀÔ´Ï´Ù. FDA¿¡ ÀÇÇÑ ¿Ü°ú¿ë Á¤Çü¿Ü°ú ½Ã¸àÆ®ÀÇ ¾ö°ÝÇÑ ½ÂÀÎ °úÁ¤Àº ½ÅÁ¦Ç°ÀÇ Ãâ½Ã¸¦ Áö¿¬½Ãŵ´Ï´Ù. FDA´Â ¾ÈÀü°ú È¿´É¿¡ ´ëÇÑ ´õ ¸¹Àº ÀÓ»ó µ¥ÀÌÅ͸¦ ¿ä±¸Çϰí ÀÖÀ¸¸ç, ±× °á°ú Ãß°¡ R&D ÅõÀÚ°¡ ÇÊ¿äÇÕ´Ï´Ù. ÷´Ü ½Ã¸àÆ®¿¡µµ ºÒ±¸Çϰí ÇÊ¿äÇÑ ÀÓ»ó µ¥ÀÌÅ͸¦ °®Ãá ºñ¿ë È¿À²ÀûÀÎ ¿É¼ÇÀÌ ¿©ÀüÈ÷ ¿ä±¸µÇ°í ÀÖÀ¸¸ç ½ÃÀå »ýÁ¸¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. »À ½ºÅ×ÀÌÇðú Á¤Çü¿Ü°ú¿ë Çɰú °°Àº ´ëüǰµµ °í±Þ °ñ ½Ã¸àÆ®ÀÇ º¸±ÞÀ» ¹æÇØÇÕ´Ï´Ù.

ÁÖ¿ä ¹ßÀü

  • 2022³â 8¿ù-Graftys´Â Arthrex¿Í °íµµ ÇÕ¼º °ñ À̽ÄÀç¿¡ °üÇÑ ´Ù³â°£ °ø±Þ °è¾àÀ» °»½Å. ÀÌ °è¾àÀº ÃÖ÷´Ü ¼ºÇü »ý¹°ÇÐÀû ±â¼úÀ» »ç¿ëÇÏ¿© ¿©·¯ °¡Áö »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Á¦°øÇß½À´Ï´Ù. Çõ½Å ÁÖµµÇü ÀÇ·á±â¼ú ±â¾÷ÀÎ Graftys´Â ÇÕ¼º °ñ»ýü Àç·áÀÇ °³¹ß°ú Á¦Á¶¿¡ Èû¾²°í ÀÖ½À´Ï´Ù. ÀÌ È¸»ç´Â ÀÓ»ó Áõ°Å¿Í À¯·´ÀÇ ÁÖ¿ä Çмú ¿¬±¸ ±â°ü°úÀÇ Á¦ÈÞ¸¦ ±â¹ÝÀ¸·Î ÇÑ Æ÷Æ®Æú¸®¿À¸¦ ÅëÇØ »À »ýü Àç·áÀÇ ¼³°è, Á¦Á¶ ¹× ÆÇ¸Å¿¡¼­ ÁÖ¿ä ±â¾÷ÀÌ µÉ °ÍÀ» ¸ñÇ¥·ÎÇÕ´Ï´Ù.
  • 2022³â 6¿ù-¸»·¹ÀÌ½Ã¾Æ KPower Bhd´Â ÀÚȸ»ç Granulab(M) Sdn Bhd¸¦ ÅëÇØ ±¹³» ÃÖÃÊÀÇ ÇÒ¶ö ÀÎÁõ ÇÕ¼º °ñ ½Ã¸àÆ®ÀÎ Prosteomax¸¦ µµÀÔÇß½À´Ï´Ù. ÀÌ ÀλêÄ®½· ±â¹Ý ½Ã¸àÆ®´Â 7°³±¹¿¡¼­ CEÀÎÁõÀ» ¹Þ°í ¸»·¹ÀÌ½Ã¾Æ À̽½¶÷ °³¹ß±¹(Jakim)À¸·ÎºÎÅÍ ÇÒ¶öÀÎÁõÀ» ¹Þ¾Ò½À´Ï´Ù. ¶ÇÇÑ Á¤Çü¿Ü°ú¿ë, µÎ°³¿ë, Ä¡°ú¿ë, ÅÎ ¾È¸é¿ëÀ¸·Î ¸»·¹ÀÌ½Ã¾Æ ÀÇ·á±â±â±¹¿¡ µî·ÏµÇ¾î ÀÖ½À´Ï´Ù. GranulabÀº ¸»·¹À̽þÆÀÇ ÇÒ¶ö Á¦Ç°ÀÎ °ú¸³ ÇÕ¼º °ñ ÀÌ½ÄÆí GranuMasµµ »ý»êÇϰí ÀÖ½À´Ï´Ù. ÀÌ È¸»ç´Â ¸»·¹À̽þƿ¡¼­ º´¿ø ¿î¿µ ȸ»ç°¡ µÉ ¼ö ÀÖµµ·Ï ÈÄ»ý¼º°ú ÇùÀÇ ÁßÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • ½ÃÀå °³¿ä
  • ½ÃÀå Á¤ÀÇ
  • Á¶»ç ¹üÀ§
  • ½ÃÀå ¼¼ºÐÈ­
  • ÅëÈ­
  • ÀüÁ¦Á¶°Ç
  • ±âÁØ ¹× ¿¹Ãø¿¬µµ ŸÀÓ¶óÀÎ
  • ÀÌÇØ °ü°èÀÚÀÇ ÁÖ¿ä ÀÌÁ¡

Á¦2Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¼³°è
  • Á¶»ç °úÁ¤

Á¦3Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä Á¶»ç °á°ú

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • Porter's Five Forces ºÐ¼®
  • ¾÷°è ¹ë·ùüÀÎ ºÐ¼®
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ

Á¦5Àå °ñ ½Ã¸àÆ® ½ÃÀå : À¯Çüº°

  • ¼Ò°³
  • Æú¸®¸ÞÆ¿¸ÞŸũ¸±·¹ÀÌÆ®
    • ½ÃÀå ±âȸ ¹× µ¿Çâ
    • ¼ºÀå Àü¸Á
    • Áö¸®Àû ÀÌÀͼº
  • ÀλêÄ®½·
    • ½ÃÀå ±âȸ ¹× µ¿Çâ
    • ¼ºÀå Àü¸Á
    • Áö¸®Àû ÀÌÀͼº
  • À¯¸® Æú¸®¾ËÄɳ뿡ÀÌÆ®
    • ½ÃÀå ±âȸ ¹× µ¿Çâ
    • ¼ºÀå Àü¸Á
    • Áö¸®Àû ÀÌÀͼº

Á¦6Àå °ñ ½Ã¸àÆ® ½ÃÀå : Á¡µµº°

  • ¼Ò°³
  • ÀúÁ¡µµ
    • ½ÃÀå ±âȸ ¹× µ¿Çâ
    • ¼ºÀå Àü¸Á
    • Áö¸®Àû ÀÌÀͼº
  • ÁßÁ¡µµ
    • ½ÃÀå ±âȸ ¹× µ¿Çâ
    • ¼ºÀå Àü¸Á
    • Áö¸®Àû ÀÌÀͼº
  • °íÁ¡µµ
    • ½ÃÀå ±âȸ ¹× µ¿Çâ
    • ¼ºÀå Àü¸Á
    • Áö¸®Àû ÀÌÀͼº

Á¦7Àå °ñ ½Ã¸àÆ® ½ÃÀå : Ç×»ýÁ¦ À¯Çüº°

  • ¼Ò°³
  • °ÕŸ¸¶À̽Å
    • ½ÃÀå ±âȸ ¹× µ¿Çâ
    • ¼ºÀå Àü¸Á
    • Áö¸®Àû ÀÌÀͼº
  • Åäºê¶ó¸¶À̽Å
    • ½ÃÀå ±âȸ ¹× µ¿Çâ
    • ¼ºÀå Àü¸Á
    • Áö¸®Àû ÀÌÀͼº
  • ¼¼ÇÁ·Ï½É
    • ½ÃÀå ±âȸ ¹× µ¿Çâ
    • ¼ºÀå Àü¸Á
    • Áö¸®Àû ÀÌÀͼº

Á¦8Àå °ñ ½Ã¸àÆ® ½ÃÀå : ¿ëµµº°

  • ¼Ò°³
  • Àΰø°üÀý ġȯ¼ú
    • ½ÃÀå ±âȸ ¹× µ¿Çâ
    • ¼ºÀå Àü¸Á
    • Áö¸®Àû ÀÌÀͼº
  • ôÃß ¼ºÇü¼ú
    • ½ÃÀå ±âȸ ¹× µ¿Çâ
    • ¼ºÀå Àü¸Á
    • Áö¸®Àû ÀÌÀͼº
  • ±âŸ
    • ½ÃÀå ±âȸ ¹× µ¿Çâ
    • ¼ºÀå Àü¸Á
    • Áö¸®Àû ÀÌÀͼº

Á¦9Àå °ñ ½Ã¸àÆ® ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¼Ò°³
  • º´¿ø ¹× Ŭ¸®´Ð
    • ½ÃÀå ±âȸ ¹× µ¿Çâ
    • ¼ºÀå Àü¸Á
    • Áö¸®Àû ÀÌÀͼº
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
    • ½ÃÀå ±âȸ ¹× µ¿Çâ
    • ¼ºÀå Àü¸Á
    • Áö¸®Àû ÀÌÀͼº

Á¦10Àå °ñ ½Ã¸àÆ® ½ÃÀå : Áö¿ªº°

  • ¼Ò°³
  • ºÏ¹Ì
    • À¯Çüº°
    • Á¡µµº°
    • Ç×»ýÁ¦ À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
    • ±¹°¡º°
  • ³²¹Ì
    • À¯Çüº°
    • Á¡µµº°
    • Ç×»ýÁ¦ À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
    • ±¹°¡º°
  • À¯·´
    • À¯Çüº°
    • Á¡µµº°
    • Ç×»ýÁ¦ À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
    • ±¹°¡º°
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • À¯Çüº°
    • Á¡µµº°
    • Ç×»ýÁ¦ À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
    • ±¹°¡º°
  • ¾Æ½Ã¾Æ ÅÂÆò¾ç
    • À¯Çüº°
    • Á¡µµº°
    • Ç×»ýÁ¦ À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
    • ±¹°¡º°

Á¦11Àå °æÀï ȯ°æ ¹× ºÐ¼®

  • ÁÖ¿ä ±â¾÷ ¹× Àü·« ºÐ¼®
  • ½ÃÀå Á¡À¯À² ºÐ¼®
  • ÇÕº´, Àμö, ÇÕÀÇ ¹× Çù¾÷
  • °æÀï ´ë½Ãº¸µå

Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • DePuy Synthesis(Part of Johnson & Johnson)
  • Stryker
  • Zimmer Biomet
  • Tecres SpA
  • Synimed Synergie Ingenierie Medicale SARL
  • Olympus Corporation
  • Heraeus holdings
  • Teknimed
  • Exactech Inc.
  • DJO, LLC
LYJ

The global bone cement market is expected to grow at a CAGR of 5.67% over the forecast period to reach US$2.619 billion by 2029 from US$1.780 billion in 2022.

Bone cement refers to a synthetic biomaterial obtained from mixing polymethyl methacrylate (PMMA), calcium phosphate, or glass polyalkenoate powder with a liquid monomer. The cement has a super gluing feature owing to which it has high applicability in orthopedical surgical procedures such as hip, knee, and joint replacement. The self-healing nature and the ability to work as artificial joints are what drives the demand for bone cement in the medical field.

The growing prevalence of fatal injuries, accidents, and orthopedical surgical producers, coupled with the rising old age population, has provided more growth opportunities to the global bone cement market. For instance, according to the data provided by the US Bureau of Labor Statistics, in 2019, the number of fatal work injuries that occurred in the US stood at 5,333, which showed a significant increase of 10.3% in comparison to the 4,836 injuries that occurred in 2015.

With such an increase in fatal injuries, the scope of bone cement usage for the treatment of any bone-related injury also increases, thereby boosting the market demand and growth of the global bone cement market during the forecast period. The global bone cement market is segmented into polymethyl methacrylate, calcium phosphate, and glass polyalkenoate. The polymethyl methacrylate segment is expected to grow at a relatively higher rate during the forecast period of the global bone cement market.

Polymethyl Methacrylate has rich mechanical strength, minimal toxicity, and provides improved self-curing properties owing to which it has high applicability during joint prostheses fixation. Hence, acting as a space filler between the bone and the implant, PMMA bone cement improves the fixation of the implant. The high-performance features of polymethyl acrylate bone cement, coupled with its cost-effectiveness and high durability, are expected to increase its demand for joint prostheses surgeries in the future, thereby boosting its segment growth as well as the overall global bone cement market growth during the forecast period.

Market Drivers:

  • The rapid increase in the number of orthopedic surgeries is driving the market demand for bone cement.

Bone cement has high applicability in orthopedical surgical procedures where the damaged bone part is replaced with a prosthesis, and to hold the prosthesis in its place, bone cement is used. The number of orthopedical surgical procedures has shown a significant increase over the years owing to the growing number of joint & bone pain in people, especially in old age, coupled with growing cases of osteoarthritis and road accidents. For instance, according to the annual report by the American Academy of Orthopedic Surgeons, in 2021, the number of knee and hip bone replacement surgeries stood at 2.4 million in the US, which showed an increase of 18.3% in comparison to the number of surgical procedures conducted in 2020.

Furthermore, according to the 2022 annual report of the Australia Orthopaedic Association National Joint Replacement Surgery Registry, in 2021, the total number of joint replacement surgeries reported in 2021 Australia stood at 1.85 million, of which knee replacement held the largest share of 68,466, followed by hips replacement with 52,787. The overall increase in joint replacement surgeries in 2021 was 7.6% in comparison to 2020's joint replacement surgical volume.

With such an increase in the number of orthopedic surgical procedures, the demand and consumption of bone cement to act as a gap filler in bones are also anticipated to increase, thereby providing a positive outlook for the global bone cement market growth during the forecast period. However, the extensive cost incurred in preparing bone cement coupled with implant complications is projected to hamper the global cement market growth during the forecast period.

  • Increasing incidence of joints and bone injuries would propel the bone cement market.

The bone cement market is driven by the increasing number of sports injuries, which often require orthopedic interventions. Bone cement, also known as polymethylmethacrylate, is used in joint replacement procedures to anchor implants to the bone. The global increase in sports participation and physical activities has led to an increase in sports-related injuries, particularly those affecting bones and joints.

Advancements in bone cement technology, such as antibiotic-loaded cement to prevent infections or improved biocompatibility, make it a preferred choice in various orthopedic applications. The aging population and increased emphasis on maintaining an active lifestyle result in a higher prevalence of degenerative joint conditions and sports-related injuries, driving the demand for orthopedic procedures.

Orthopedic procedures involving bone cement can support rehabilitation, allowing individuals to regain mobility and function. The global bone cement market expansion is expected to continue due to the impact of sports injuries.

Market Restraints:

  • High expenses and stringent clinical data requirements could restrain the market growth.

The development of bone cement is a costly and time-consuming process that requires significant R&D investments. The FDA's stringent approval process for surgical orthopedic cement delays new product releases. The FDA demands more clinical data for safety and efficacy, resulting in additional R&D investments. Despite advanced cements, there is still a need for cost-effective options with required clinical data, affecting market survival. Alternatives like bone staples and orthopedic pins also hinder the uptake of advanced bone cement.

Key Developments:

  • August 2022- Graftys renewed its multi-year supply agreement with Arthrex for advanced synthetic bone graft materials. The agreement provided multiple new business opportunities using state-of-the-art orthobiologic technology. Graftys, an innovation-driven medtech company, is committed to the development and manufacturing of synthetic bone biomaterials. The company aims to become a major player in the design, manufacturing, and distribution of bone biomaterials, with a portfolio built on clinical evidence and partnerships with leading academic research institutions in Europe.
  • June 2022- Malaysia's KPower Bhd introduced Prosteomax, the country's first halal-certified synthetic bone cement, through its subsidiary Granulab (M) Sdn Bhd. The calcium phosphate-based cement received CE certification in seven countries and halal certification from the Islamic Development Department Malaysia (Jakim). It is registered with the Malaysian Medical Device Authority for orthopaedics, cranial, dental, and maxillofacial applications. Granulab also produces granular synthetic bone grafts, GranuMas, a halal product in Malaysia. The company is in talks with the Health Ministry to become a hospital operator in Malaysia.

Market Segmentation:

By Type

  • Polymethyl Methacrylate
  • Calcium Phosphate
  • Glass Polyalkenoate

By Viscosity

  • Low
  • Medium
  • High

By Antibiotics Type

  • Gentamicin
  • Tobramycin
  • Cefuroxime

By Application

  • Arthroplasty
  • Kyphoplasty
  • Vertebroplasty
  • Others

By End-User

  • Hospitals & Clinics
  • Ambulatory Surgical Center

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • United Arab Emirates
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL BONE CEMENT MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Polymethyl Methacrylate
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Calcium Phosphate
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Glass Polyalkenoate
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness

6. GLOBAL BONE CEMENT MARKET BY VISCOSITY

  • 6.1. Introduction
  • 6.2. Low
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Medium
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. High
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL BONE CEMENT MARKET BY ANTIBIOTICS TYPE

  • 7.1. Introduction
  • 7.2. Gentamicin
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Tobramycin
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Cefuroxime
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL BONE CEMENT MARKET BY APPLICATION

  • 8.1. Introduction
  • 8.2. Arthroplasty
    • 8.2.1. Market Opportunities and Trends
    • 8.2.2. Growth Prospects
    • 8.2.3. Geographic Lucrativeness
  • 8.3. Kyphoplasty
    • 8.3.1. Market Opportunities and Trends
    • 8.3.2. Growth Prospects
    • 8.3.3. Geographic Lucrativeness
  • 8.4. Vertebroplasty
    • 8.4.1. Market Opportunities and Trends
    • 8.4.2. Growth Prospects
    • 8.4.3. Geographic Lucrativeness
  • 8.5. Others
    • 8.5.1. Market Opportunities and Trends
    • 8.5.2. Growth Prospects
    • 8.5.3. Geographic Lucrativeness

9. GLOBAL BONE CEMENT MARKET BY END-USER

  • 9.1. Introduction
  • 9.2. Hospitals & Clinics
    • 9.2.1. Market Opportunities and Trends
    • 9.2.2. Growth Prospects
    • 9.2.3. Geographic Lucrativeness
  • 9.3. Ambulatory Surgical Center
    • 9.3.1. Market Opportunities and Trends
    • 9.3.2. Growth Prospects
    • 9.3.3. Geographic Lucrativeness

10. GLOBAL BONE CEMENT MARKET BY GEOGRAPHY

  • 10.1. Introduction
  • 10.2. North America
    • 10.2.1. By Type
    • 10.2.2. By Viscosity
    • 10.2.3. By Antibiotics Type
    • 10.2.4. By Application
    • 10.2.5. By End-User
    • 10.2.6. By Country
      • 10.2.6.1. USA
        • 10.2.6.1.1. Market Opportunities and Trends
        • 10.2.6.1.2. Growth Prospects
      • 10.2.6.2. Canada
        • 10.2.6.2.1. Market Opportunities and Trends
        • 10.2.6.2.2. Growth Prospects
      • 10.2.6.3. Mexico
        • 10.2.6.3.1. Market Opportunities and Trends
        • 10.2.6.3.2. Growth Prospects
  • 10.3. South America
    • 10.3.1. By Type
    • 10.3.2. By Viscosity
    • 10.3.3. By Antibiotics Type
    • 10.3.4. By Application
    • 10.3.5. By End-User
    • 10.3.6. By Country
      • 10.3.6.1. Brazil
        • 10.3.6.1.1. Market Opportunities and Trends
        • 10.3.6.1.2. Growth Prospects
      • 10.3.6.2. Argentina
        • 10.3.6.2.1. Market Opportunities and Trends
        • 10.3.6.2.2. Growth Prospects
      • 10.3.6.3. Others
        • 10.3.6.3.1. Market Opportunities and Trends
        • 10.3.6.3.2. Growth Prospects
  • 10.4. Europe
    • 10.4.1. By Type
    • 10.4.2. By Viscosity
    • 10.4.3. By Antibiotics Type
    • 10.4.4. By Application
    • 10.4.5. By End-User
    • 10.4.6. By Country
      • 10.4.6.1. Germany
        • 10.4.6.1.1. Market Opportunities and Trends
        • 10.4.6.1.2. Growth Prospects
      • 10.4.6.2. France
        • 10.4.6.2.1. Market Opportunities and Trends
        • 10.4.6.2.2. Growth Prospects
      • 10.4.6.3. United Kingdom
        • 10.4.6.3.1. Market Opportunities and Trends
        • 10.4.6.3.2. Growth Prospects
      • 10.4.6.4. Italy
        • 10.4.6.4.1. Market Opportunities and Trends
        • 10.4.6.4.2. Growth Prospects
      • 10.4.6.5. Spain
        • 10.4.6.5.1. Market Opportunities and Trends
        • 10.4.6.5.2. Growth Prospects
      • 10.4.6.6. Others
        • 10.4.6.6.1. Market Opportunities and Trends
        • 10.4.6.6.2. Growth Prospects
  • 10.5. Middle East and Africa
    • 10.5.1. By Type
    • 10.5.2. By Viscosity
    • 10.5.3. By Antibiotics Type
    • 10.5.4. By Application
    • 10.5.5. By End-User
    • 10.5.6. By Country
      • 10.5.6.1. Saudi Arabia
        • 10.5.6.1.1. Market Opportunities and Trends
        • 10.5.6.1.2. Growth Prospects
      • 10.5.6.2. Israel
        • 10.5.6.2.1. Market Opportunities and Trends
        • 10.5.6.2.2. Growth Prospects
      • 10.5.6.3. United Arab Emirates
        • 10.5.6.3.1. Market Opportunities and Trends
        • 10.5.6.3.2. Growth Prospects
        • 10.5.6.3.3.
      • 10.5.6.4. Others
        • 10.5.6.4.1. Market Opportunities and Trends
        • 10.5.6.4.2. Growth Prospects
  • 10.6. Asia Pacific
    • 10.6.1. By Type
    • 10.6.2. By Viscosity
    • 10.6.3. By Antibiotics Type
    • 10.6.4. By Application
    • 10.6.5. By End-User
    • 10.6.6. By Country
      • 10.6.6.1. China
        • 10.6.6.1.1. Market Opportunities and Trends
        • 10.6.6.1.2. Growth Prospects
      • 10.6.6.2. Japan
        • 10.6.6.2.1. Market Opportunities and Trends
        • 10.6.6.2.2. Growth Prospects
      • 10.6.6.3. South Korea
        • 10.6.6.3.1. Market Opportunities and Trends
        • 10.6.6.3.2. Growth Prospects
      • 10.6.6.4. India
        • 10.6.6.4.1. Market Opportunities and Trends
        • 10.6.6.4.2. Growth Prospects
      • 10.6.6.5. Australia
        • 10.6.6.5.1. Market Opportunities and Trends
        • 10.6.6.5.2. Growth Prospects
      • 10.6.6.6. Indonesia
        • 10.6.6.6.1. Market Opportunities and Trends
        • 10.6.6.6.2. Growth Prospects
      • 10.6.6.7. Thailand
        • 10.6.6.7.1. Market Opportunities and Trends
        • 10.6.6.7.2. Growth Prospects
      • 10.6.6.8. Taiwan
        • 10.6.6.8.1. Market Opportunities and Trends
        • 10.6.6.8.2. Growth Prospects
      • 10.6.6.9. Others
        • 10.6.6.9.1. Market Opportunities and Trends
        • 10.6.6.9.2. Growth Prospects

11. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 11.1. Major Players and Strategy Analysis
  • 11.2. Market Share Analysis
  • 11.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 11.4. Competitive Dashboard

12. COMPANY PROFILES

  • 12.1. DePuy Synthesis (Part of Johnson & Johnson)
  • 12.2. Stryker
  • 12.3. Zimmer Biomet
  • 12.4. Tecres SpA
  • 12.5. Synimed Synergie Ingenierie Medicale S.A.R.L
  • 12.6. Olympus Corporation
  • 12.7. Heraeus holdings
  • 12.8. Teknimed
  • 12.9. Exactech Inc.
  • 12.10. DJO, LLC
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦